A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients with Refractory/Relapsed Acute Leukemias or High-Risk Myelodysplastic Syndromes.

Trial Profile

A Dose Escalation Safety and Pharmacokinetic Study of SAR103168 Administered as a Single Agent by Intravenous Infusion, Once Daily for 5 Consecutive Days to Patients with Refractory/Relapsed Acute Leukemias or High-Risk Myelodysplastic Syndromes.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Feb 2015

At a glance

  • Drugs SAR 103168 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Mar 2012 Actual patient number is 30 as reported by ClinicalTrials.gov. record.
    • 31 Dec 2011 Status changed from recruiting to discontinued.
    • 13 Sep 2011 Planned end date changed from Jun 2012 to Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top